Substituted fatty acids for treating non-alcoholic steatohepatitis
The present disclosure relates to a method of preventing and/or treating non-alcoholic steatohepatitis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of Formula (II): wherein R 1 , R2, R3, X and Y are as defined in the specification; or a pharmaceutically acceptable salt, solvate, or solvate of such a salt. More particularly, the present disclosure relates to a method of preventing and/or treating non-alcoholic steatohepatitis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of Formula (I): wherein R2, R 3 , and X, are as defined in the specification; or a pharmaceutically acceptable salt, solvate, or solvate of such a salt. Further, the present invention relates to a compound of Formula (I) for preventing and/or treating non-alcoholic steatohepatitis, wherein R 2 , R 3 and X are as defined in the specification; or a pharmaceutically acceptable salt, solvate, or solvate of such a salt.
1. A method for treating non-alcoholic steatohepatitis in a subject, wherein the method comprises administering to the subject in need thereof a pharmaceutical composition comprising at least one pharmaceutically acceptable excipient and a pharmaceutically effective amount of 2-(((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenyl)oxy)butanoic acid of the following formula:
2. The method of claim 1 , wherein the pharmaceutical composition is administered to the subject once daily.
3. The method of claim 1 , wherein the method further comprises reducing fecal bile content of the subject.
4. The method of claim 1 , wherein the method further comprises reducing hepatic cholesterol in the subject.
5. A method for reducing hepatic inflammation and hepatic steatosis in a subject having non-alcoholic steatohepatitis, wherein the method comprises administering to the subject in need thereof a pharmaceutical composition comprising at least one pharmaceutically acceptable excipient and a pharmaceutically effective amount of 2-(((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenyl)oxy)butanoic acid of the following formula:
6. The method of claim 5 , wherein the pharmaceutical composition is administered to the subject once daily.
7. The method of claim 5 , wherein the method further comprises reducing fecal bile content of the subject.
8. The method of claim 5 , wherein the method further comprises reducing hepatic cholesterol in the subject.
9. A method for reducing hepatic inflammation in a subject having non-alcoholic steatohepatitis, wherein the method comprises administering to the subject in need thereof a pharmaceutical composition comprising at least one pharmaceutically acceptable excipient and a pharmaceutically effective amount of 2-(((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenyl)oxy)butanoic acid of the following formula:
10. The method of claim 9 , wherein the pharmaceutical composition is administered to the subject once daily.
11. The method of claim 9 , wherein the method further comprises reducing fecal bile content of the subject.
12. The method of claim 9 , wherein the method further comprises reducing hepatic cholesterol in the subject.